S56 - Movement Disorders: Huntington's Disease and Drug-Induced Dyskinesias

Event Time: Friday April 28, 2017 3:30 pm to 5:30 pm
Topic(s): Movement Disorders
Director(s):
Description: A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts.
Completion Message:
CME Credits: 2
Core Competencies:

Abstract Presenters

Start Time Pub. Title Presenter
3:30 PM 001 Selectivity and Biodistribution of WVE-120101, a Potential Antisense Oligonucleotide Therapy for the Treatment of Huntington′s Disease Meena M
Disclosure:
Dr. Vargeese has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Wave Life Sciences Ltd..

3:42 PM 002 Huntingtin As a Scaffold for Selective Macroautophagy Erin Furr-Stimming, MD
Disclosure:
Dr. Zhang has nothing to disclose.

3:54 PM 003 Pooled Analysis of Phase 3 studies of ADS-5102 (amantadine hydrochloride) extended release capsules for Levodopa-Induced Dyskinesia: A detailed review of UDysRS Results Rajesh Pahwa, MD, FAAN
Disclosure:
Dr. Pahwa has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbvie, ACADIA, Acorda, Adamas, Cynapses, Global Kinetics, Lundbeck, Neurocrine, Pfizer, Sage, Sunovion, Teva Neuroscience and US World Meds. Dr. Pahwa has received research support from Abbvie, Adamas, Avid, Biotie, Boston Scientific, Civitas, Cynapses, Kyowa, National Parkinson Foundation, NIH/NINDS, Parkinson Study Group.

4:06 PM 004 Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Improvements in Clinical Global Impression of Change (CGIC) with Deutetrabenazine Treatment in Moderate to Severe Tardive Dyskinesia (TD) Hubert H. Fernandez, MD, FAAN
Disclosure:
Dr. Fernandez has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Prime Education, Inc., International Parkinson and Movement Disorders Society, Carling Communications, Medscape, AbbVie, Biogen, GE Health Care, Inventiv, Kyowa Hakko Kirin, Lundbeck, Merz Pharmaceuticals, Voyager, Sunovion, and Pfizer. Dr. Fernandez has received personal compensation in an editorial capacity for International Parkinson and Movement Disorders Society for serving as Medical Editor of the MDS Web Site. Dr. Fernandez has received research support from AbbVie, Acadia, Teva, Biotie/Acorda Therapeutics, Civitas, Kyowa/Prostrakan, Michael J. Fox Foundation, Movement Disorders Society, NIH/NINDS, Parkinson Study Group, Rhythm, and Synosia.

4:18 PM 005 Efficacy of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia: Results of a Long-Term Study (KINECT 3 Extension) Stewart Factor, DO, FAAN
Disclosure:
Dr. Factor has nothing to disclose.

4:30 PM 006 Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Effect of Fixed-Dose Deutetrabenazine by Baseline Comorbidities Karen E. Anderson
Disclosure:
Dr. Anderson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with North American study Co-Principal Investigator for LEGATO-HD, Global Principal Investigator for AIM-TD, and Global Co-Principal Investigator for ARM-TD. Site Principal Investigator for Pride-HD, First-HD, ARC-HD: Teva. Scientific Advisor, Site Principal I.

4:42 PM 007 Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Efficacy, Safety, and Tolerability of Fixed-Dose Deutetrabenazine for the Treatment of Moderate to Severe Tardive Dyskinesia (TD) Karen E. Anderson
Disclosure:
Dr. Anderson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with North American study Co-Principal Investigator for LEGATO-HD, Global Principal Investigator for AIM-TD, and Global Co-Principal Investigator for ARM-TD. Site Principal Investigator for Pride-HD, First-HD, ARC-HD: Teva. Scientific Advisor, Site Principal I.

4:54 PM 008 Safety of OnabotulinumtoxinA Treatment With Concomitant Antithrombotic Therapy in Patients With Post-stroke Spasticity: A Pooled Analysis of Randomized, Double-Blind Studies Rozalina Dimitrova, MD, MPH
Disclosure:
Dr. Dimitrova has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan plc, employee. Dr. Dimitrova holds stock and/or stock options in Stock and stock options in Allergan plc, which sponsored research in which Dr. Dimitrova was involved as an investigator.

Register Now

Related Courses